Nutlin-3A for treatment of proliferative vitreoretinopathy

1. A method for inhibiting or reducing the severity of proliferative vitreoretinopathy (PVR) comprising:

identifying a subject comprising a reduction of intra-ocular p53, thereby identifying a subject suffering from PVR; and

contacting retinal pigment epithelial cells and/or glial cells in an eye of said subject with a composition comprising Nutlin-3a (RG7112/RO5045337) in a sufficient amount that reduces the intra-ocular reduction of the level of p53, thereby inhibiting or reducing the severity of PVR.

2. A method for inhibiting or reducing the severity of proliferative vitreoretinopathy (PVR) comprising:

identifying a subject comprising a reduction of intra-ocular p53, thereby identifying a subject suffering from PVR; and

contacting retinal pigment epithelial cells and/or glial cells in an eye of said subject with a composition comprising Nutlin-3a (RG7112/RO5045337) in a sufficient amount that prevents p53 from interacting with human double min 2 (Hdm2), thereby reducing the intra-ocular reduction of the level of p53 and inhibiting or reducing the severity of PVR .

3. The method of claim 1 , wherein said Nutlin-3a is administered at a concentration of 0.1 μM, 0.5 μM, 1.0 μM, 2.0 μM, 5 μM, 10 μM, 20 μM, 30 μM, or 50 μM.

4. The method of claim 1 , wherein said Nutlin-3a is present in a concentration of 0.1-10% (mg/ml).

5. The method of claim 1 , wherein said composition is administered intravitreally or subconjunctivally.

6. The method of claim 1 , wherein said intra-ocular reduction is a platelet-derived growth factor receptor α (PDGFRα)-mediated reduction.

7. The method of claim 1 , wherein said subject suffering from PVR has undergone rhegmatogenous retinal detachment surgery.

8. The method of claim 1 , wherein the subject is older than 24 months of age.

9. The method of claim 1 , wherein said composition prevents retinal detachment in said subject.

10. The method of claim 1 , wherein said composition reduces the formation of epiretinal membranes in said subject.

11. The method of claim 1 , wherein said composition inhibits the contraction of retinal pigment epithelial (RPE) cells in said subject.

12. The method of claim 1 , wherein said composition is administered every 48 hours, every 24 hours, every 12 hours, or every 6 hours.

13. The method of claim 1 , wherein said composition is administered for 1 day, 3 days, 7 days, 14 days, 30 days, 60 days, 90 days, 120 days, or 365 days.

14. The method of claim 1 , wherein said composition further comprises a pharmaceutically acceptable carrier.

15. The method of claim 1 , wherein the form of said composition is a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension.

16. The method of claim 1 , wherein said subject is a human.

17. The method of claim 1 , wherein said subject has not been diagnosed with a retinoblastoma.

18. The method of claim 1 , wherein the structure of said Nutlin-3a comprises